CLARKE JOHN K 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Jun 4, 2018
Insider Transaction Report
Form 4
CLARKE JOHN K
Director
Transactions
- Sale
Common Stock
2018-05-31$99.38/sh−2,758$274,090→ 21,133 total - Sale
Common Stock
2018-05-31$101.37/sh−2,100$212,877→ 8,991 total - Exercise/Conversion
Stock Option (right to buy)
2018-05-31−15,000→ 0 totalExercise: $27.28From: 2009-06-03Exp: 2018-06-02→ Common Stock (15,000 underlying) - Sale
Common Stock
2018-05-31$100.33/sh−10,042$1,007,514→ 11,091 total - Sale
Common Stock
2018-05-31$101.97/sh−100$10,197→ 8,891 total - Exercise/Conversion
Common Stock
2018-05-31$27.28/sh+15,000$409,200→ 23,891 total
Footnotes (4)
- [F1]All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018.
- [F2]Sales prices ranged from $98.89 to $99.75.
- [F3]Sales prices ranged from $99.92 to $100.90.
- [F4]Sales prices ranged from $100.97 to $101.88.